The project presented aims to develop a new generation of antibody banks to improve the selection of final antibodies from the early stages of development. This bank will eventually be exploited by academics for the benefit of collaborative research and the partner company imab for the benefit of the industrial world. The development and validation of this bank should make it possible to enhance the know-how of the academic team “functional targeting and screening of cancer”, while involving the partner company which will validate the results achieved with a view to a transfer to the industrial world. The research programme “Synthabiomed” brings together INSERM, through the laboratory of the Institut Régional du Cancer in Montpellier, and the company imab.